<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200926048842N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-09-29</date_registration>
      <primary_sponsor>Zahedan University of Medical Sciences</primary_sponsor>
      <public_title>The Effect of Continuous Care Model on Quality of Life in Patients Thalassemia Major</public_title>
      <acronym></acronym>
      <scientific_title>Examining the Effect of Continuous Care Model on Quality of Life in Patients with Thalassemia Major</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-08-13</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>60</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/51218</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Other design features: After selection, in order to standardize the research conditions for the two groups of intervention and control, a special random method will be used. If the patient is in the intervention group, the prosecution care model is implemented, but no intervention was performed for the control group, Randomization description: Sampling will be done by available methods. The selected patients are then randomly divided into control and intervention groups. First, an envelope containing the name of the group is prepared and randomly arranged for the total number of people studied, and by referring to and gradually selecting the individuals, one of the cards will be assigned to them, which determines the group of individuals in the intervention group or Will be in control. Due to random sampling, the samples will have an equal chance of being selected in both intervention and control groups.</study_design>
      <phase>N/A</phase>
      <hc_freetext>The effect of continuous care on the quality of life of patients with thalassemia major.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: At first, the quality of life questionnaire of the World Health Organization will be provided to them, and after answering it, four stages of the follow-up care model, which include familiarization, sensitization, control and evaluation; In the first stage, the researcher introduces himself to the patient and explains the purpose of the work to him, and in the second stage, which is the main stage of the intervention and includes 6 training sessions in the period of 45-60 minutes, The training class of the hospital was intended; Formation and after the completion of 6 training sessions, the third stage, which is control and follow-up, has begun, and in this stage, the patient for 3 months after the intervention, weekly and based on the arrangements made before and during the familiarization stage. , Calls the patient and asks him what he has been taught, and with the patient's answer, he enters the care checklist prepared, and the fourth stage, which is evaluation, is divided into two stages, once a month after the intervention and once Another three months after the intervention; The desired questionnaire is provided to individuals. Also the content of each session is as follows. Session 1: Anatomy and physiology of blood and thalassemia. In this session, what are the types of blood cells, hemoglobin, thalassemia ?, What are the causes of thalassemia ?, Types of thalassemia, What are the risk factors in thalassemia? Diagnosis of thalassemia major, symptoms of the disease will be explained. Session 2: Complications of the disease, treatment of thalassemia In this session, questions and answers from the first session, abnormal increase in iron, symptoms and effects of increased iron load, other complications of the disease, types of thalassemia treatment will be explained. Session 3: Diet and exercise in thalassemia patients In this session, questions and answers from the previous session, iron, calcium, vitamin D, the main antioxidants including vitamin E and vitamin C, carotenoids, flavonoids, the effect of exercise on thalassemia will be explained. . Session 4: Basic treatment in thalassemia and treatment complications. In this question and answer session from the previous session, injectable blood transfusion. Complications of blood transfusion. Desferal iron overload and how it works, contraindications and precautions in desferrioxamine, side effects of desferrioxamine, drug interactions, drug administration, patient evaluation and drug effects will be explained. Session 5: Teaching your relaxation techniques. In this question and answer session from the previous session, what are the relaxation methods? Deep breathing, advanced relaxation, body scan meditation, mindfulness, imaging meditation, (training and practice), how the technique Incorporate relaxation into everyday life? Will be explained and implemented. Session 6: Social skills improvement training. In this session, practicing self-relaxation techniques, the previous session, 12 social skills strategies will be explained and summarized. Also, at the end of the last session, all the items that have been explained in person to the patient and his family are made available to the patient and the family in the form of a booklet so that they can use it if necessary. Intervention 2: Control group: Initially, the WHO Quality of Life Questionnaire will be provided to them, and after completing the questionnaire, no intervention will be made other than the usual treatment procedures that are performed for patients in the ward. One month and three months after the completion of the questionnaire that was presented in the first session of patient service, the same questionnaires will be provided to the patients of the target group again to assess their quality of life score again. At the end of three months and after completing the questionnaire, the educational booklet that was held for the members of the intervention group in person, will be provided to this group of patients to use its educational content.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mahnaz Ghaljeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 19, Alley 12, Shohada Lebanon, Tehran St.</address>
        <city>Sahroud</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3619676483</zip>
        <telephone>+98 23 3237 3188</telephone>
        <email>ssn.shahroud@yahoo.com</email>
        <affiliation>Zahedan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mahnaz Ghaljeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 19, Alley 12, Shohada Lebanon, Tehran St.</address>
        <city>Shahroud</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>3619676483</zip>
        <telephone>+98 23 3237 3188</telephone>
        <email>ssn.shahroud@yahoo.com</email>
        <affiliation>Zahedan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age over 18 years
No problems such as mental retardation, behavioral and mental disorders, hearing, speech according to medical records
Ability to access and control the patient during 3 months
Complete consent of the patient and family to refer and follow up by phone and, if necessary, in person for care and to continue the training and care counseling required by the researcher
Resident of Zahedan
Having a cell phone in person or in the family or having a landline at home
Failure to participate in similar training courses
Have a minimum literacy
Get a quality of life score less than 50 from the WHOQOL-BREF Quality of Life Questionnaire</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Reluctance to continue cooperation
Incidence of severe physical complications from the disease</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>D56.1</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Beta thalassaemia</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: At first, the quality of life questionnaire of the World Health Organization will be provided to them, and after answering it, four stages of the follow-up care model, which include familiarization, sensitization, control and evaluation; In the first stage, the researcher introduces himself to the patient and explains the purpose of the work to him, and in the second stage, which is the main stage of the intervention and includes 6 training sessions in the period of 45-60 minutes, The training class of the hospital was intended; Formation and after the completion of 6 training sessions, the third stage, which is control and follow-up, has begun, and in this stage, the patient for 3 months after the intervention, weekly and based on the arrangements made before and during the familiarization stage. , Calls the patient and asks him what he has been taught, and with the patient's answer, he enters the care checklist prepared, and the fourth stage, which is evaluation, is divided into two stages, once a month after the intervention and once Another three months after the intervention; The desired questionnaire is provided to individuals. Also the content of each session is as follows. Session 1: Anatomy and physiology of blood and thalassemia. In this session, what are the types of blood cells, hemoglobin, thalassemia ?, What are the causes of thalassemia ?, Types of thalassemia, What are the risk factors in thalassemia? Diagnosis of thalassemia major, symptoms of the disease will be explained. Session 2: Complications of the disease, treatment of thalassemia In this session, questions and answers from the first session, abnormal increase in iron, symptoms and effects of increased iron load, other complications of the disease, types of thalassemia treatment will be explained. Session 3: Diet and exercise in thalassemia patients In this session, questions and answers from the previous session, iron, calcium, vitamin D, the main antioxidants including vitamin E and vitamin C, carotenoids, flavonoids, the effect of exercise on thalassemia will be explained. . Session 4: Basic treatment in thalassemia and treatment complications. In this question and answer session from the previous session, injectable blood transfusion. Complications of blood transfusion. Desferal iron overload and how it works, contraindications and precautions in desferrioxamine, side effects of desferrioxamine, drug interactions, drug administration, patient evaluation and drug effects will be explained. Session 5: Teaching your relaxation techniques. In this question and answer session from the previous session, what are the relaxation methods? Deep breathing, advanced relaxation, body scan meditation, mindfulness, imaging meditation, (training and practice), how the technique Incorporate relaxation into everyday life? Will be explained and implemented. Session 6: Social skills improvement training. In this session, practicing self-relaxation techniques, the previous session, 12 social skills strategies will be explained and summarized. Also, at the end of the last session, all the items that have been explained in person to the patient and his family are made available to the patient and the family in the form of a booklet so that they can use it if necessary.</i_keyword>
      <i_keyword>Control group: Initially, the WHO Quality of Life Questionnaire will be provided to them, and after completing the questionnaire, no intervention will be made other than the usual treatment procedures that are performed for patients in the ward. One month and three months after the completion of the questionnaire that was presented in the first session of patient service, the same questionnaires will be provided to the patients of the target group again to assess their quality of life score again. At the end of three months and after completing the questionnaire, the educational booklet that was held for the members of the intervention group in person, will be provided to this group of patients to use its educational content</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Quality of life score, which is measured by the World Health Organization quality of life questionnaire and its score range is from 26-130. Timepoint: It is before the start of the intervention and one month and three months after the end of the intervention. Method of measurement: The World Health Organization Quality of Life Questionnaire, which is a 26-item questionnaire and includes 4 subscales. And the difference between the two is 28; Mental Health Sub-Scale: The sum of the scores of questions 5-6-7-11-19-26 in the questionnaire The range of scores of this subscale will be between 6 and 30 and the difference between the two is 24; Social Interface Sub-Scale: The sum of the scores of questions 20-21-22 in the questionnaire The range of scores of this sub-scale will be between 3 and 15 and the difference between the two is 12; Environmental Health Sub-Scale: The sum of the scores of the questions 8-9- 12-13- 14-23-24-25 25 in the questionnaire The range of scores of this subscale will be between 8 and 40 and the difference between the two is 32; Quality of life and general health: The sum of the scores of questions 1 and 2 in the questionnaire The range of scores of this subscale will be between 2 to 10 and the difference between the two is 8.</prim_outcome>
      <prim_outcome>Physical health score that is measured by the World Health Organization quality of life questionnaire and its score range is from 7-35. Timepoint: It is before the start of the intervention and one month and three months after the end of the intervention. Method of measurement: The World Health Organization Quality of Life Questionnaire, which is a 26-item questionnaire and includes 4 subscales. Physical Health Sub-Scale: The sum of the scores of the questions 3- 4- 10- 15-16-17-18 in the questionnaire. The range of scores of this subscale will be between 7 and 35. ; And the difference between the two is 28.</prim_outcome>
      <prim_outcome>Mental health score that is measured by the World Health Organization quality of life questionnaire and its score range is from 6-30. Timepoint: It is before the start of the intervention and one month and three months after the end of the intervention. Method of measurement: The World Health Organization Quality of Life Questionnaire, a 26-item questionnaire that includes four subscales of mental health subscale: Total scores of questions in the questionnaire 5- 6 -7 -11- 19- 26 subscale scores range between 6 to 30 will be the difference These two are 24.</prim_outcome>
      <prim_outcome>Social relations health score that is measured by the World Health Organization quality of life questionnaire and its score range is from 3-15. Timepoint: It is before the start of the intervention and one month and three months after the end of the intervention. Method of measurement: The World Health Organization Quality of Life Questionnaire, which is a 26-item questionnaire and includes 4 subscales; Social Relations Sub-Scale: The sum of the scores of the questions 20-21-22 in the questionnaire The range of scores of this sub-scale will be between 3 and 15 and the difference between the two is 12.</prim_outcome>
      <prim_outcome>Environmental health score that is measured by the World Health Organization quality of life questionnaire and its score range is from 8-40. Timepoint: It is before the start of the intervention and one month and three months after the end of the intervention. Method of measurement: World Health Organization Quality of Life Questionnaire, which is a 26-item questionnaire and includes 4 subscales, Environmental Health Sub-Scale: Total scores of questions 8-9- 12-13-14-23-24-25 in the range of scores of this subscale between 8 Will be 40 and the difference between the two is 32.</prim_outcome>
      <prim_outcome>Quality of life and general health score that is measured by the World Health Organization quality of life questionnaire and its score range is from 2-10. Timepoint: It is before the start of the intervention and one month and three months after the end of the intervention. Method of measurement: The World Health Organization Quality of Life Questionnaire, which is a 26-item questionnaire and includes 4 subscales; Quality of life and general health: The sum of the scores of questions 1 and 2 in the questionnaire The range of scores of this subscale will be between 2 and 10 and the difference between the two is 8.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Zahedan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-08-09</approval_date>
        <contact_name>Ethics Committee of Zahedan University of Medical Sciences</contact_name>
        <contact_address>Dr. Hesabi Square - Campus of Medical Sciences zahedan Sistan-va-Balouchestan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
